FMP

FMP

Enter

TBIO - Telesis Bio, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/TBIO.png

Telesis Bio, Inc.

TBIO

OTC

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis. It also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

0.43 USD

0.1499 (34.86%)

Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

4.8M

6.58M

11.04M

27.43M

27.51M

41.61M

62.94M

95.21M

144.02M

217.85M

Revenue %

-

36.86

67.93

148.44

0.27

51.26

51.26

51.26

51.26

Operating Cash Flow

-6.39M

-15.38M

-36.7M

-38.72M

-34.67M

-41.61M

-62.94M

-95.21M

-144.02M

-217.85M

Operating Cash Flow %

-132.99

-233.9

-332.32

-141.12

-126.02

-100

-100

-100

-100

Cap Ex

-79k

-204k

-1.85M

-4.47M

-1.98M

-3.75M

-5.67M

-8.57M

-12.97M

-19.61M

Cap Ex %

-1.64

-3.1

-16.79

-16.29

-7.2

-9

-9

-9

-9

Free Cash Flow

-6.47M

-15.59M

-38.55M

-43.18M

-36.65M

-45.36M

-68.61M

-103.78M

-156.99M

-237.46M

Weighted Average Cost Of Capital

Price

0.43

Beta

Diluted Shares Outstanding

1.66M

Costof Debt

9.03

Tax Rate

After Tax Cost Of Debt

9.03

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

34.38M

Total Equity

713.08k

Total Capital

35.09M

Debt Weighting

97.97

Equity Weighting

2.03

Wacc

9.07

Build Up Free Cash Flow

Year

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Revenue

4.8M

6.58M

11.04M

27.43M

27.51M

41.61M

62.94M

95.21M

144.02M

217.85M

Operating Cash Flow

-6.39M

-15.38M

-36.7M

-38.72M

-34.67M

-41.61M

-62.94M

-95.21M

-144.02M

-217.85M

Cap Ex

-79k

-204k

-1.85M

-4.47M

-1.98M

-3.75M

-5.67M

-8.57M

-12.97M

-19.61M

Free Cash Flow

-6.47M

-15.59M

-38.55M

-43.18M

-36.65M

-45.36M

-68.61M

-103.78M

-156.99M

-237.46M

Wacc

9.07

9.07

9.07

9.07

9.07

Pv Lfcf

-41.58M

-57.67M

-79.98M

-110.91M

-153.81M

Sum Pv Lfcf

-443.95M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

9.07

Free Cash Flow T1

-242.21M

Terminal Value

-3.42B

Present Terminal Value

-2.22B

Intrinsic Value

Enterprise Value

-2.66B

Net Debt

32.81M

Equity Value

-2.69B

Diluted Shares Outstanding

1.66M

Equity Value Per Share

-1.62k

Projected DCF

-1624.77 1%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep